Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2446-2449

  Grossman, Trudy H ^a   O'Brien, William ^a,b   Kerstein, Kathryn O ^a   Sutcliffe, Joyce A ^a  

^a Tetraphase Pharmaceuticals   (United States)

^b Intelligent MDx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; CRYSTAL VIOLET; ERAVACYCLINE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RIBOSOME SUBUNIT; STAINING; UROPATHOGENIC ESCHERICHIA COLI; BACTERIAL COUNT; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; COLISTIN; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI INFECTIONS; GENTAMICINS; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; TETRACYCLINES; THIENAMYCINS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84928919899     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04967-14     Document Type: Article

References (18)

1. Fux CA, Costerton JW, Steward PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends Microbiol 13:34-40. http://dx.doi.org/10.1016/j.tim.2004.11.010.
2. Costerton JW, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. 2003. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112:1466-1477. http://dx.doi.org/10.1172/JCI20365.
3. Hung C, Zhou Y, Pinkner JS, Dodson KW, Crowley JR, Heuser J, Chapman MR, Hadjifrangiskou M, Henderson JP, Hultgren SJ. 2013. Escherichia coli biofilms have an organized and complex extracellular matrix structure. mBio 4:e00645-13. http://dx.doi.org/10.1128/mBio.00645-13.
4. Costerton JW, Steward PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
5. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
6. Blango MG, Mulvey MA. 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855-1863. http://dx.doi.org/10.1128/AAC.00014-10.
7. Hall-Stoodley L, Stoodley P. 2009. Evolving concepts in biofilm infections. Cell Microbiol 11:1034-1043. http://dx.doi.org/10.1111/j.1462-5822.2009.01323.x.
8. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-107. http://dx.doi.org/10.1126/science.1084550.
9. Lewis K. 2001. Riddle of biofilm resistance. Antimicrob Agents Chemother 45:999-1007. http://dx.doi.org/10.1128/AAC.45.4.999-1007.2001.
10. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230:13-18. http://dx.doi.org/10.1016/S0378-1097(03)00856-5.
11. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
12. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. CLSI, Wayne, PA.
13. Xiao X-Y, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Ronn M, Sun C, Zhang W-Y, Sutcliffe JA. 2012. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597-605. http://dx.doi.org/10.1021/jm201465w.
14. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559-2564. http://dx.doi.org/10.1128/AAC.06187-11.
15. Bowler LL, Zhanel GG, Blake Ball T, Saward LL. 2012. Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of Ceftazidime. Antimicrob Agents Chemother 56:4976-4979. http://dx.doi.org/10.1128/AAC.00650-12.
16. Haagensen JAJ, Kalusen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, Molin S. 2007. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 189:28-37. http://dx.doi.org/10.1128/JB.00720-06.
17. Ishida H, Ishida Y, Kurosaka Y, Otani T, Sato K, Kobayashi H. 1998. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother 42:1641-1645.
18. Stone G, Wood P, Dixon L, Keyhan M, Matin A. 2002. Tetracycline rapidly reaches all the constituent cells of uropathogenic Escherichia coli biofilms. Antimicrob Agents Chemother 46:2458-2461. http://dx.doi.org/10.1128/AAC.46.8.2458-2461.2002.